Literature DB >> 18725861

Regional myo-inositol concentration in mild cognitive impairment Using 1H magnetic resonance spectroscopic imaging.

Małgorzata Siger1, Norbert Schuff, Xiaoping Zhu, Bruce L Miller, Michael W Weiner.   

Abstract

The goal was to assess regional patterns of metabolite abnormalities in mild cognitive impairment (MCI) and Alzheimer disease (AD) patients using proton magnetic resonance spectroscopy imaging at 1.5 Tesla. Fourteen MCI, 17 AD, and 16 healthy control (HC) subjects were studied. MCI was associated with higher myo-inositol (mIn) concentration in right parietal white matter compared with HC and lower mIn levels in frontal white matter compared with AD. AD was associated with higher mIn concentration in frontal and parietal white matter compared with HC. N-acetylaspartate (NAA) concentration of white matter was similar in all groups, whereas NAA concentration of gray matter showed a trend toward lower values in the right parietal lobe in AD compared with MCI and HC. A mIn increase in white matter in absence of significant NAA reduction suggests that mIn is a more robust and sensitive marker of white matter pathology in AD and MCI than NAA. Furthermore, the dissociation between mIn and NAA alterations in white matter could provide important information regarding the role of glial and neuronal damage in MCI and AD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18725861      PMCID: PMC3039549          DOI: 10.1097/WAD.0b013e3181875434

Source DB:  PubMed          Journal:  Alzheimer Dis Assoc Disord        ISSN: 0893-0341            Impact factor:   2.703


  41 in total

1.  Region and tissue differences of metabolites in normally aged brain using multislice 1H magnetic resonance spectroscopic imaging.

Authors:  N Schuff; F Ezekiel; A C Gamst; D L Amend; A A Capizzano; A A Maudsley; M W Weiner
Journal:  Magn Reson Med       Date:  2001-05       Impact factor: 4.668

2.  Correlation between cognitive status and cerebral inositol in Alzheimer-type dementia.

Authors:  A M Salvan; M Ceccaldi; S Confort-Gouny; C Milandre; P J Cozzone; J Vion-Dury
Journal:  J Neurol       Date:  1998-10       Impact factor: 4.849

3.  Short echo time multislice proton magnetic resonance spectroscopic imaging in human brain: metabolite distributions and reliability.

Authors:  D Wiedermann; N Schuff; G B Matson; B J Soher; A T Du; A A Maudsley; M W Weiner
Journal:  Magn Reson Imaging       Date:  2001-10       Impact factor: 2.546

4.  Inflammatory CNS demyelination: histopathologic correlation with in vivo quantitative proton MR spectroscopy.

Authors:  A Bitsch; H Bruhn; V Vougioukas; A Stringaris; H Lassmann; J Frahm; W Brück
Journal:  AJNR Am J Neuroradiol       Date:  1999-10       Impact factor: 3.825

5.  Selective reduction of N-acetylaspartate in medial temporal and parietal lobes in AD.

Authors:  N Schuff; A A Capizzano; A T Du; D L Amend; J O'Neill; D Norman; J Kramer; W Jagust; B Miller; O M Wolkowitz; K Yaffe; M W Weiner
Journal:  Neurology       Date:  2002-03-26       Impact factor: 9.910

6.  Regional metabolic patterns in mild cognitive impairment and Alzheimer's disease: A 1H MRS study.

Authors:  K Kantarci; C R Jack; Y C Xu; N G Campeau; P C O'Brien; G E Smith; R J Ivnik; B F Boeve; E Kokmen; E G Tangalos; R C Petersen
Journal:  Neurology       Date:  2000-07-25       Impact factor: 9.910

7.  Mild cognitive impairment represents early-stage Alzheimer disease.

Authors:  J C Morris; M Storandt; J P Miller; D W McKeel; J L Price; E H Rubin; L Berg
Journal:  Arch Neurol       Date:  2001-03

8.  (1)H-MR spectroscopy differentiates mild cognitive impairment from normal brain aging.

Authors:  M Catani; A Cherubini; R Howard; R Tarducci; G P Pelliccioli; M Piccirilli; G Gobbi; U Senin; P Mecocci
Journal:  Neuroreport       Date:  2001-08-08       Impact factor: 1.837

9.  Alzheimer disease: absolute quantification of cerebral metabolites in vivo using localized proton magnetic resonance spectroscopy.

Authors:  G Stoppe; H Bruhn; P J Pouwels; W Hänicke; J Frahm
Journal:  Alzheimer Dis Assoc Disord       Date:  2000 Apr-Jun       Impact factor: 2.703

10.  FDG PET imaging in patients with pathologically verified dementia.

Authors:  J M Hoffman; K A Welsh-Bohmer; M Hanson; B Crain; C Hulette; N Earl; R E Coleman
Journal:  J Nucl Med       Date:  2000-11       Impact factor: 10.057

View more
  16 in total

1.  Quantitative multivoxel proton MR spectroscopy study of brain metabolites in patients with amnestic mild cognitive impairment: a pilot study.

Authors:  Zhong-Xian Yang; Shan-Shan Huo; Xiao-Fang Cheng; Zhi-Feng Xu; Zhen Cao; Jie-Xia Zeng; Ye-Yu Xiao; Ke-Zeng You; Wei Chen; Yan-Yan Liu; Ren-Hua Wu
Journal:  Neuroradiology       Date:  2011-07-08       Impact factor: 2.804

2.  Fast water concentration mapping to normalize (1)H MR spectroscopic imaging.

Authors:  Angèle Lecocq; Yann Le Fur; Alexis Amadon; Alexandre Vignaud; Patrick J Cozzone; Maxime Guye; Jean-Philippe Ranjeva
Journal:  MAGMA       Date:  2014-06-08       Impact factor: 2.310

Review 3.  Various MRS application tools for Alzheimer disease and mild cognitive impairment.

Authors:  F Gao; P B Barker
Journal:  AJNR Am J Neuroradiol       Date:  2014-04-17       Impact factor: 3.825

4.  Imaging the Alzheimer brain.

Authors:  J Wesson Ashford; Ahmad Salehi; Ansgar Furst; Peter Bayley; Giovanni B Frisoni; Clifford R Jack; Osama Sabri; Maheen M Adamson; Kerry L Coburn; John Olichney; Norbert Schuff; Daniel Spielman; Steven D Edland; Sandra Black; Allyson Rosen; David Kennedy; Michael Weiner; George Perry
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

Review 5.  Mitochondrial dysfunction, oxidative stress, neuroinflammation, and metabolic alterations in the progression of Alzheimer's disease: A meta-analysis of in vivo magnetic resonance spectroscopy studies.

Authors:  Tao Song; Xiaopeng Song; Chenyawen Zhu; Regan Patrick; Miranda Skurla; Isabella Santangelo; Morgan Green; David Harper; Boyu Ren; Brent P Forester; Dost Öngür; Fei Du
Journal:  Ageing Res Rev       Date:  2021-10-29       Impact factor: 10.895

6.  Identification of metabolic correlates of mild cognitive impairment in Parkinson's disease using magnetic resonance spectroscopic imaging and machine learning.

Authors:  Hakan Gurvit; Esin Ozturk-Isik; Sevim Cengiz; Dilek Betul Arslan; Ani Kicik; Emel Erdogdu; Muhammed Yildirim; Gokce Hale Hatay; Zeynep Tufekcioglu; Aziz Müfit Uluğ; Basar Bilgic; Hasmet Hanagasi; Tamer Demiralp
Journal:  MAGMA       Date:  2022-07-22       Impact factor: 2.533

7.  MICEST: a potential tool for non-invasive detection of molecular changes in Alzheimer's disease.

Authors:  Mohammad Haris; Anup Singh; Kejia Cai; Kavindra Nath; Rachelle Crescenzi; Feliks Kogan; Hari Hariharan; Ravinder Reddy
Journal:  J Neurosci Methods       Date:  2012-10-03       Impact factor: 2.390

8.  Proton magnetic resonance spectroscopy in 22q11 deletion syndrome.

Authors:  Fabiana da Silva Alves; Erik Boot; Nicole Schmitz; Aart Nederveen; Jacob Vorstman; Christina Lavini; Petra J Pouwels; Petra Pouwels; Lieuwe de Haan; Don Linszen; Therese van Amelsvoort
Journal:  PLoS One       Date:  2011-06-30       Impact factor: 3.240

9.  Role of emerging neuroimaging modalities in patients with cognitive impairment: a review from the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012.

Authors:  Amer M Burhan; Robert Bartha; Christian Bocti; Michael Borrie; Robert Laforce; Pedro Rosa-Neto; Jean-Paul Soucy
Journal:  Alzheimers Res Ther       Date:  2013-07-08       Impact factor: 6.982

10.  The bioenergetic status relates to dopamine neuron loss in familial PD with PINK1 mutations.

Authors:  Rüediger Hilker; Ulrich Pilatus; Carsten Eggers; Johann Hagenah; Julia Roggendorf; Simon Baudrexel; Johannes C Klein; Bernd Neumaier; Gereon R Fink; Helmuth Steinmetz; Christine Klein; Elke Hattingen
Journal:  PLoS One       Date:  2012-12-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.